U.S. Healthcare Spending’s Meager Return On Investment

The United States spends more on healthcare than any other nation, yet its citizens live shorter, sicker lives. A growing body of data reveals a stark truth: America's massive investment yields a meager return on investment (ROI) in terms of health outcomes, life expectancy, and system efficiency.

The U.S. healthcare system is a paradox of high expenditure and poor performance. In 2025, total national health expenditures exceeded $4.8 trillion, accounting for roughly 18% of GDP. Per capita spending surpassed $14,000 — more than double the average of other developed countries. Yet the U.S. ranks last among peer nations on key metrics such as life expectancy, infant mortality, and preventable hospitalizations. This disconnect is not new, but recent analyses from the Commonwealth Fund and the Peterson-KFF Health System Tracker underscore its persistence and deepening.

Why does the U.S. get so little for its money? A major factor is administrative complexity. The multi-payer system, with private insurers, Medicare, Medicaid, and other programs, creates enormous overhead: administrative costs consume an estimated 25% of total spending, compared to less than 10% in single-payer systems. Additionally, prices for medical services, prescription drugs, and hospital stays are far higher in the U.S. than elsewhere, often with no corresponding quality advantage. For instance, an MRI costs over $1,400 on average in the U.S. versus roughly $350 in Switzerland. The fee-for-service payment model also incentivizes volume over value, leading to overtesting and overtreatment.

The consequences are measured in human lives. While the U.S. saw a slight improvement in life expectancy after the COVID-19 pandemic, it remains at 77.5 years — more than three years below the OECD average. Chronic disease rates, especially for diabetes, heart disease, and obesity, are higher. Access remains deeply unequal: 26 million Americans were uninsured in 2024, and many more are underinsured, delaying care due to cost. These disparities drive worse population health, dragging down the overall ROI.

Policymakers and experts are pushing reforms, but progress is slow. The Biden administration's efforts to lower drug prices through the Inflation Reduction Act and to expand coverage through enhanced subsidies have had modest impact. On the state level, some experimenting with global budgets (like Maryland) or value-based payment models show promise. However, the political landscape remains polarized, with debates over a public option or Medicare for All stalling in Congress. Private sector innovators are also stepping in: employers are increasingly adopting direct primary care and telemedicine to curb costs, while insurers like Cigna and UnitedHealth invest in care coordination.

Looking ahead, the U.S. healthcare system faces a critical crossroads. The Congressional Budget Office projects that federal health spending will rise to $2 trillion by 2030, driven by an aging population and rising chronic disease prevalence. Without structural change, the ROI will only worsen. Key milestones to watch include the expiration of enhanced ACA subsidies in 2025, potential drug price negotiations under Medicare expansion, and the growing adoption of price-transparency rules. The question is whether the U.S. can finally learn from other countries and build a system that delivers the health outcomes its massive spending should guarantee.